Original Investigation  April 25, 2024 Disparities in Mortality by Sexual Orientation in a Large, Prospective Cohort of Female Nurses Sarah McKetta, Tabor Hoatson, Landon D. Hughes, et al JAMA. 2024;331(19):1638-1645. doi:10.1001/jama.2024.4459 Key Points Question  Do bisexual and lesbian women have higher risks of premature mortality than heterosexual women? Findings  Bisexual and ...

Editor's Note  May 20, 2024 Tracking Physical Activity One Step at a Time Cary P. Gross, Raegan W. Durant JAMA Intern Med. Published online May 20, 2024. doi:10.1001/jamainternmed.2024.0898 Current physical activity guidelines recommend at least 150 minutes per week of moderate-intensity physical activity or 75 minutes per week of vigorous activity. These time thresholds were based on studies using self-reported activity, which is prone to bi...

Original Investigation  April 24, 2024 Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study Cynthia Gyamfi-Bannerman, Rebecca G. Clifton, Alan T. N. Tita, et al JAMA. 2024;331(19):1629-1637. doi:10.1001/jama.2024.4303 Key Points Question  Is administration of antenatal corticosteroids to individuals at risk of late preterm delivery, originally shown ...

Original Investigation  May 20, 2024 Time- vs Step-Based Physical Activity Metrics for Health Rikuta Hamaya, Eric J. Shiroma Jr, Christopher C. Moore, et al JAMA Intern Med. Published online May 20, 2024. doi:10.1001/jamainternmed.2024.0892 Key Points Question  Should women in their 60s or older rely on a clock or step counter for monitoring their physical activity (PA) levels for health? ...

Low vs High Blood Pressure Targets in Critically Ill and Surgical Patients In ICU Thu, 25 Apr 2024 The treatment of critically ill and perioperative patients often involves targeting blood pressure as a cornerstone of haemodynamic management. Current guidelines suggest maintaining high blood pressure targets for these patients based on observational studies linking hypotensive events to adverse outcomes. However, these recommendations are not...

Original Investigation  May 20, 2024 Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis Renata Iskander, Hannah Moyer, Karine Vigneault, et al JAMA. Published online May 20, 2024. doi:10.1001/jama.2024.6281 Key Points Question  Is patient participation in cancer drug trials associated with longer survival? Findings ...

Editorial  May 19, 2024 When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis Ana C. Zamora, Victor E. Ortega, Eva M. Carmona JAMA. Published online May 19, 2024. doi:10.1001/jama.2024.8776 Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease that inevitably results in respiratory failure and death within 3 to 5 years of diagnosis.1 No effective treatment for IPF existed until the appr...

Navigating the Implementation of AI in Intensive Care Medicine In ICU Mon, 22 Apr 2024 Intensive care medicine is recognised as a promising field for implementing artificial intelligence (AI) due to the abundance of data generated in intensive care units (ICUs). However, despite the potential benefits, there is a significant gap between developed AI models and their actual clinical use. Challenges include technological issues in data quality, ethical a...

ARTICLES|ONLINE FIRST Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial Jürgen Beck, Christian Fung, Daniel Strbian, et al Lancet Published: May 15, 2024 DOI:https://doi.org/10.1016/S0140-6736(24)00702-5 Summary Background It is unknown whether decompressive craniectomy improves clinical outcome for peopl...

Original Investigation  May 19, 2024 Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial Ganesh Raghu, Luca Richeldi, Evans R. Fernández Pérez, et al JAMA. Published online May 19, 2024. doi:10.1001/jama.2024.8693 Key Points Question  Does the connective tissue growth factor inhibitor pamrevlumab decrease the rate of decline in lung function for patients wit...